Rick Simpson Oil (RSO) i le Manu’a District: O se Tusitusiga Atoa e OilWell Cannabis

Afai e te nofo i le Manu’a District — le filifiliaga atoa o motu matautia e aofia ai Ofu, Olosega, ma Ta’u — e te malamalama lea o le uiga o le fa’alagolago i le aiga (family), le pulea, ma le poto masani na fa’aauauina e tausaga. O le olaga iinei e ave i se ala ese. O le sami e taute, o le eleele e fa’avae, ma afai e tasi i lou aiga e mafatia e le mama, ma’i, po’o le fa’alavelave o fa’afefea maualuga, e saili ai ni tali e fa’amanuaina le tino ma le agaga.

O lenei le mafua’aga ua matou fa’asoa atu nei ia te outou. I OilWell Cannabis, matou te talitonu e tatau ona maua e tagata o le Manu’a District le aafia tasi i le cannabinoid faaolataga fa’amalamalama, e tusia i su’esu’ega, sa fesoasoani ai i afa tausaga e tagata Texas e toe maua ai latou olaga mai le mama maualuga, fa’afefea o le moe, popole, ma le afa o aoga fa’afomai fa’asolosolo. E le o matou nei e fa’atau atu “snake oil.” O le taua o matou e tuuina atu ai lelei sili lea o le moni — e lagolagoina e saienisi, ta’usia e taula’i, ma tuuina atu i le fa’aaloalo tasi e fautua ai e outou i outou tagata.

Talaaga mulimuli i le RSO: O le tofiga a Rick Simpson ma lona fa’aiuga

O ai o Rick Simpson?

O Rick Simpson o se fa’atufugaga paoa mai Nova Scotia, Canada, na mafatia i se fa’alavelave i le galuega i le 1997 na ia maua ai le mama maualuga, tinnitus, ma se fa’afomai e leai se tali. Ina ua le mafai le fomai fa’asolosolo, na fesoasoani le cannabis. I le 2003, ina ua fa’ato’atoa ona ia faaaoga le suauu cannabis e togafiti ai e tolu le pa i lo lona tino, na taua mai e vave ona ave ese i le asa foa — se mea na maua ai le talaaga “Rick Simpson Oil.”

Fa’amatalaga taua: O nei mea na silafia e talaaga loloto fa’atasi, e le o su’esu’ega fa’aa’oa’o e fa’amatalaina e tagata. E le faia e Simpson se su’esu’ega fa’asolosolo, e le tusiina e se su’esu’ega, e leai ni lana tali ua fa’amautu e isi . Na fa’ateleina lana tala i le 2005 talaaga Run From the Cure, na avea ai le RSO ma se fa’ailoga o le tōfā fa’asoa mo tagata e maua i le ma’i kanesa, mama maualuga, ma so’o se tasi na fa’asa’o e le fa’afomai fa’aleOfisa .

Lana fa’atulagaga 60-gram, 90-aso

Na talitonu e Simpson e tatau ona ‘a’ai e se tagata ma’i kanesa tusa ma le 60 gram o suauu THC-maualuga i le 90 aso. Lana fa’atulagaga na amata i le 0.5 gram o le fa’apapa o loe e tolu taimi i aso ma fa’ateleina i le 1 gram i le aso i le vaiaso lima . I le taimi lea, o se tagata e ‘a’ai i le 600–900 mg o delta‑9 THC i asilaulau — aofaiga e sili atu nai lo so’o se mea na su’esu’e i fa’atulagaga fa’amautu .

Le mafua’aga ua le atoa lana metotia

Na faia la’au a Simpson mai se la’au indisa sili, fa’ato’atoa e naphtha po’o le isopropyl alcohol (solvents e le mafai ona ‘a’ai), ma fa’apipi’i i le vevela maualuga na fasia ai so’o se terpene. Na maua ai se mea uliuli e pei o le kesi e leai se malosi fa’atulaga, leai se su’esu’ega fa’amau, ma leai se fa’amaoniogaina o le saogalemu .

Na maua ai lena i se vaitaimi ua le fa’atagaina le cannabis, ae na tu’ua tu’e ai tagata i:

• Solvents ua toe i ai (e aofia ai benzene po’o isi kanesa)
• Tulaga THC e ese i batch e ese
• Leai se mea o le terpene, na ‘aveese ai le avanoa o le fa’amanuiaga o entourage
• Leai se avanoa e pulea le psychoactivity mo le aso

E le lagolagoina e talaaga o tagata le fa’apuupuuga a Simpson e “faitino” le ma’i kanesa. Ua talia e le National Cancer Institute (NCI) le mafua’aga o su’esu’ega ta’aloga ae e le lagolagoina le cannabis o se lavea mo le ma’i kanesa . Na fa’amaonia e le FDA na cannabinoids fa’apea (Epidiolex, dronabinol) mo fa’amanuiaga fa’apitoa — e le o le la’au cannabis atoa [1].

O mea sa sa’o e Simpson

Na fa’aitiitia e ia le cannabis. Na tu’uina atu lana suauu e aunoa ma se totogi, na a’oa’oina isi e faia, ma fa’ia se malaga na fa’atōfāina ai suesuega ma fa’atonuga . O lena tofiga e manaia — ma o le mafua’aga na matou fausia ai se mea sili.

Traditional RSO fa’atusatusa ma le RSO fa’atulagaina o le teri

Tulaga	Traditional RSO	OilWell RSO (Manu’a District edition)
Mea o le la’au	Se la’au indisa sili THC	Fa’apipi’i cannabinoid mai hemp eseese
Fa’ato’atoaina	Naphtha po’o le isopropyl alcohol	Solvent-free fa’apipi’i o distillates maualuga i organic MCT oil
Fa’atulagaga cannabinoid	60–90% delta‑9 THC, le pulea	7 cannabinoids i fa’atulaga milligram sa’o (vaai i lalo)
Mea o le terpene	Fasia e le vevela	Live terpenes i le 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
Fa’atulagaga	Leai se; ese i batch	Su’esu’ega i lab; 553 mg/mL cannabinoids atoa i pepa ta’asolo
Su’esu’ega i lab	E le faia	Full panel: malosi, terpenes, pesticide, metala maualuga, solvents toe, microbes
Solvents toe	E mafai ona aofia ai benzene i le naphtha	Solvent zero; MCT oil lava
Sa’o o le doini	Fa’atauina e syringe	Dropper graduated e 0.1 mL increments (55.3 mg cannabinoids)
Fomata oloa	Suauu kese lava	Sublingual oil + vape cartridge (fa’atulaga fa’apitoa)
Teuina o le THCa	Fa’atomi decarboxylation	1,500 mg THCa teuina ua; e te pulea pe a (po’o a) fa’ateleina
A’oa’iga fa’amaoni	Talaaga loloto fa’atasi	Fa’auo su’esu’ega fa’atulagaina; e i ai tusi manatu mo mea ta’asolo

Uiga o OilWell Cannabis: Mai se lima ta’ai o se maile i se misi e fa’asala i moana

Le amataga: Talaaga o Bentley

Na fanauina OilWell i Houston, Texas, ae o le fatu o lo matou misi o se maile e igoa o Bentley. Ina ua ma’i Bentley, na fautuaina e fomai ma’i e pei le oti — e faa’ai le meaai mama i ona organ, na fai, e ma’i tele lona lima i luma. O Colin Valencia, lo matou fa’avae, na te le talia le fautua. Sa ia le’iloa so’o se uo i le fa’alavelave o le McAllen-Reynosa borderlands; e le mafai ona ia leiloa lana maile.

O se tagata fesoasoani e igoa o Jessica na fesiligia Colin le fesili na suia le mea uma: “Ua te’eina e te le tele o le weed ae e te le fa’alogo i le CBD?” O lena nofo galo na avea ai ma misi. Na a’oa’i Colin e faaaoga se CBD golden paste mo Bentley — se fa’apipi’i o organic turmeric, coconut oil, black pepper, ma CBD oil. I le isi aso, na tu’e lelei Bentley, na savali i le Colin, ma na fa’aavatu mai lana polo. Mai le lima ta’ai i le taaalo. E le tali fau ma’imau le maile. O le faaolataga cannabinoid moni lena.

Na nonofo toe tene ai Bentley i le 10 tausaga, na oti natura i le 20 tausaga. I lena tekau, na atiina le Colin ni fa’atulaga sao mo so’o tulaga fa’ato’atama’i na matau ia Bentley: neurodegeneration → CBG (neuroprotective, PPARγ agonism); dementia → CBC (neurogenesis); glaucoma → THCa (CB1 agonism, intraocular pressure); arthritis → anti-inflammation multi-pathway (CBD, CBG, THCa, caryophyllene). E le lava se cannabinoid e tasi. Na a’oa’i mai Bentley e taua le synergy.

Le fa’alavelave a Colin: PTSD ma le taofi o benzo

E le na’o le talaaga o Bentley. O le lava ia Colin i le PTSD maualuga ma le fa’alavelave benzo. Ina ua ia filifilia e taofi le Xanax vave — se mea fa’alemalo — na faaaoga e ia le lava cannabinoid ua leiloa mai lana fesoasoani i Bentley. Na fanauina le Peace Gummies i fa’atulaga taeao i le taimi o le taofi. Nei lava, e faaaoga pea e Colin le vape e pulea lona fa’afefea ma le PTSD. E nonofo o ia i le mea o matou oloa na faia e faia.

Mai le border i le Baylor Medical Center

Na tupu Colin i McAllen, Texas, o se vaega fa’aitiiti ma fa’igata i le U.S. Na a’oa’i e ia le cannabis i le ala fa’atraditional — i le pogisa, i luma o le fa’atulagaina. Ae na avea foi o ia ma engineer o le software ma na galue mo le Baylor College of Medicine, o se falemoli sili i le Texas Medical Center. O lena fa’apipi’i — poto tele i le la’au ma le sao medical — o le mea e ese ai OilWell.

Le filosofia o OilWell RSO (pae fa)

1. Aafia i luma o le fa’amau — E le mana’omia se kālefa fa’afomai. So’o se tasi e 21+ e mafai ona fa’atonu. Matou te vaaia atu i le atunuu ma le lalolagi atoa, aofia ai teritori U.S. pei o le Manu’a District. Na tu’uina atu e Simpson lana suauu e aunoa; matou te fa’atau se oloa fa’amaoni ma tusia le fa’atulaga e mafai ai e te faia pe afai e te filifilia.

2. Malosi e pulea e le tagata — O lo matou suauu sublingual e aofia ai 1,500 mg o le THCa teuina. E te pulea: faaaoga teuina (e le psychoactive) po’o fa’ateleina i le fale i le ~1,315 mg o le delta‑9 THC. Fa’atasi ma le 90 mg delta‑9 THC ua i ai, o lea o le ~1,405 mg o le THC atoa — RSO maualuga lava, fa’aletulafono ona o le fa’atulaga e tupu pe’a e fa’atau.

3. Fa’atulaga tatala — O milligram ta’asolo e tusia. Afai e le mafai ona e totogi $129.99, e mafai ona e maua ni distillates hemp-derived ma toe faia le fa’atulaga. O lena agaga na fesoasoani ai i Bentley.

4. Lagolago su’esu’ega, e le o fa’asalalau — Matou te fa’auo ia tasi su’esu’ega fa’atulagaina (vaai i le GENERAL KNOWLEDGE). E le o matou fa’apuupuuga o le faitino. O le taua o matou o le fa’amalosia.

Vaega fa’aletulafono: Farm Bill ma le fa’atulagaina THCa

O le RSO Sublingual Oil a matou e aofia na’o le 90 mg o le delta‑9 THC i le pepa ta’asolo 30 mL — fa’alalo le tulaga 0.3% fa’alea’au a le 2018 Farm Bill. O cannabinoids uma hemp-derived. O lo matou oloa o Farm Bill compliant i le taimi o le fa’atau, e mafai ai ona fa’atau, pu’e, ma vaaia atu i tele o vaega U.S.

Kemisi o le fa’atulagaina THCa:

• 1,500 mg THCa × 0.877 (fa’atulaga decarboxylation) = ~1,315 mg delta‑9 THC pe’a fa’apipi’i i le 260°F (125°C) mo 45–60 minute.
• Fa’atasi ma le 90 mg delta‑9 THC ua i ai, e pulea e te pulea pe a non-psychoactive (teuina) po’o RSO maualuga lava.

Fa’asilasilaga taua fa’aletulafono mo tagata o le Manu’a District:
O le THCa e fa’atulagaina i le delta‑9 THC pe’a fa’apipi’i. Peita’i o lo matou oloa e tutusa ma tulaga hemp a le a’au, e eseese tulaga fa’aletulafono i le American Samoa. O le toto’otoga e tatau ona e fa’amaonia e fa’atagaina hemp-derived products <0.3% delta‑9 THC i lou vaega ae e fa’atonu. Na OilWell tuuina atu uma fa’amaumauga, COA, ma riiti mo so’o se vaaiga. E le mafai ona matou fa’amaoni ai fuafuaga a vamua po’o fa’amau fa’alea’au.

Fa’atino e aunoa ma solvents ma su’esu’ega talu a talu a

Na faaaoga le RSO auau i le naphtha po’o le isopropyl alcohol — solvents e mafai ona tu’ua benzene ma isi kanesa. O la’au matou e solvent-free: matou te fa’apipi’i distillates cannabinoid maualuga ma isolates i organic MCT oil, se carrier e mafai ona ‘a’ai e fa’aleleia le mauaina sublingual ma aveese le manogi o le kesi o le RSO auau.

Su’esu’ega i lab fa’atulagaina mo so’o batch:

• Malosi (HPLC/UHPLC, ±2% sa’o)
• Metala maualuga (arsenic, cadmium, lead, mercury — fa’alalo tulaga FDA)
• Pesticides (400+ compounds via LC‑MS/MS ma GC‑MS/MS)
• Solvents toe (headspace GC, FDA Class 3 <5,000 ppm)
• Microbes (E. coli, Salmonella, Aspergillus, etc.)

COAs e maua i fa’atonuga ma i lo matou upega tafa’ilagi. E mafai ona e fa’amaonia le mea i pepa ta’asolo a’e e oo atu i lou fale i le Manu’a District.

O matou oloa: RSO Sublingual Oil & RSO Vape Cartridge

RSO Sublingual Oil – $129.99

• Tele: 30 mL (1 fl oz)
• Cannabinoids atoa: 16,590 mg (553 mg/mL)
• Fa’avae cannabinoid i pepa ta’asolo:
  • CBD: 4,500 mg – anxiolytic, anti-inflammatory, neuroprotective [3][4]
  • CBG: 3,000 mg – neuroprotection, PPARγ agonism, poto mo IBD [7][8]
  • Delta-8 THC: 6,000 mg – anti-nausea, la’au i le manaui, psychoactivity e itiiti afe [9]
  • THCa: 1,500 mg – teuina, non-psychoactive; ~1,315 mg THC pe’a fa’atulaina [12]
  • Delta-9 THC: 90 mg – THC fa’avae, fa’alalo le 0.3% limit
  • CBN: 750 mg – fa’ata’ita’i mo le moe (e pei lava o le fa’amaoniga o tagata) [16][17]
  • CBC: 750 mg – anti-inflammatory, neurogenic (preclinical) [18][19]
• Live terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Carrier: organic MCT oil
• Dropper: graduated i 0.1 mL increments (55.3 mg cannabinoids)
• O i ai: 15–45 minute (sublingual)
• Tulaga maualuga: 1–2 itula
• Taimi: 4–6 itula
• Bioavailability: 13–19%
• Doses i pepa ta’asolo: ~40–60 e fa’atulaina i le tele o le ‘a’ai

RSO Vape Cartridge – $49.99

• Tele: 1 gram
• Cannabinoids atoa: 900+ mg
• Fa’avae cannabinoid:
  • CBD 30%
  • CBG 20%
  • Delta-8 THC 15%
  • THCa 10%
  • CBN 10%
  • CBC 10%
• Live terpenes: 5%+
• Thread: 510-thread universal battery (maua fa’alea’au po’o le upega)
• O i ai: 1–2 minute (ala vave sili)
• Tulaga maualuga: 10–15 minute
• Taimi: 2–4 itula
• Bioavailability: 10–35%
• Auto-decarb: vaping i le 400–450°F na fa’atulaina le THCa → delta-9 THC vave

Afea e faaaoga ai fomata eseese i le Manu’a District

Tulaga	Fomata Lelei	Le Mafua’aga
Mama vave (e.g., pe’a uma le aso galuega i le plantation)	Vape	O i ai 1–2 minute, fesoasoani vave
Pulea le mama maualuga (arthritis, mama o le tua)	Sublingual	Taimi 4–6 itula, pulea le maualaina
Fesoasoani mo le moe (masani i tino matua)	Sublingual (1–2 mL a’e moe)	Tu’uina atu 25–50 mg CBN + entourage atoa
Fesoasoani i le aso aunoa le high (e mana’omia galue, ta’avale)	Sublingual teuina (e le vevela)	THCa e non-psychoactive; e te malamalama
Maualuga i le po (pe e mana’omia le “high” fa’amanuiaga)	Sublingual fa’atulaina po’o Vape	Fa’ateleina le THC atoa 1,405 mg
Lu’itua mai chemo po’o ma’i stomach	Vape + Sublingual	Vape mo lu’itua vave; sublingual mo manaui fa’avae
Popole po’o fa’anoanoa (fa’alavelave aiga, tupe, ese ai)	Sublingual (0.3 mL teuina)	CBD + CBG filemu e aunoa le mālō [3]

Fa’atulagaina fa’apitoa mo tulaga (fa’atulaga Manu’a District)

Fa’asilasilaga taua: O nei fa’amatalaga e a’oa’oga, e le o fa’atonuga fa’afomai. Tatalo ia lou fomai i luma o le amataina o so’o se fa’atulaga cannabinoid, fa’apitoa pe e te pē, fa’apea ai, e mafatia lou liver, po’o e faaaoga vai-tinu e feso’ota’i ma cannabinoids. E le tatau ona e ta’avale, fa’aaoga va’a, po’o fa’aaoga mea maualuga pe’a e faaaoga doses psychoactive.

Mama maualuga (e.g., arthritis, fa’afefea tuai mai galuega)

• Aso: 0.3–0.5 mL sublingual teuina (CBD + CBG + THCa) i le 6–8 itula. E teu le maualaina e aunoa le high.
• Po: 0.5–1.0 mL sublingual fa’atulaina a’e moe. Fa’apipi’i le fesoasoani THC + CBN.
• Fa’amaoni: Poto o CBD anti-inflammatory ma analgesic [4]; fesoasoani a delta-9 THC i mama puupuu [13]; CB2 activation o beta-caryophyllene [24]; COX-2 inhibition o THCa [12].

Fa’afefea o le moe (masani i matua)

• A’e moe: 1.0–2.0 mL sublingual (e tu’uina atu 25–50 mg CBN).
• Afai e te i ala i le po: 1–2 puffs vape mo o i ai vave.
• Fa’amaoni: CBN i doses 20–50 mg ua su’esu’eina mo le moe [16][17]; tusi manatu e mana’omia su’esu’ega sili ae e i ai le fa’amanuiaga o tagata [17].

Popole ma stress (fa’alavelave aiga, tupe, ese ai)

• Aso: 0.3 mL sublingual teuina (CBD 15 mg + CBG 10 mg).
• Afai e maualuga le popole: 1–2 puffs vape mo filemu vave.
• Fa’amaoni: anxiolysis o CBD i samples fa’atagata [3]; 5-HT1A activity o CBG e pei lava [7][8]; limonene e mafai ona puipuia le popole mai THC [20].

Lu’itua mai chemo ma manaui (mo e alu i LBJ po’o le moliaga ese)

• I chemo: 0.5–1.0 mL sublingual 1 itula i luma.
• Lu’itua vave: 2–3 puffs vape pe mana’omia.
• Pe’a uma: 0.5 mL sublingual i le 6 itula.
• Fa’amaoni: delta-8 THC e i ai poto antiemetic [9]; delta-9 THC ua FDA-approved mo lu’itua chemo [1][13]; CBD e mafai ona fa’aitiitia le popole [3].

Vaaiga i le Manu’a District: E fa’apefea ona e maua OilWell RSO

E te nofo i le Manu’a District. O lea e oʻo mai ai le mea e tatau ona e iloa e uiga mai le RSO i le Ofu, Olosega, po’o Ta’u.

Vaaiga fa’alea’au U.S. (aofia ai American Samoa)

• Carrier: USPS Priority Mail, FedEx Ground, po’o UPS Ground
• Taimi: 5–7 aso galuega mai Houston i le Pago Pago, fa’atasi ma le tu’uina atu i Ofu, Olosega, po’o Ta’u.
• Pusa: Discrete, e le’i va’aia le fa’ailoga cannabis. E malolosi i vevela tropical.
• Tracking: Tu’uina atu mo so’o fa’atonuga.
• Lomiga: Avanoa signature-required (fa’afautua pe e te popole).
• Tusi vamua: COA atoa, fa’amaoni hemp-derived, ma riiti.

Totogi vaaiga

• Flat rate: $12.99 mo fa’atonuga i lalo o le $150; FREE mo $150+.
• Lalolagi (afai e te nofo i fafo o le U.S.): Matou te vaaia i nisi atunuu. Totogi minimu e tu’uina; totogi tele e billed fa’asese. E te talia uma fuafuaga fa’aletulafono a vamua.

Fa’amaumauga: Peita’i o lo matou oloa e tutusa fa’alea’au, e mafai ona i ai fa’atagaina fa’apitoa i le American Samoa mo le fa’aofaina cannabinoid. Tatalo ia fa’amaonia tulaga fa’alea’au i luma o le fa’atonuga. Na OilWell tu’uina atu uma fa’amaumauga e fa’afiafia vamua, ae e le matou fa’amaonia fuafuaga a vamua po’o fa’amau fa’alea’au.

Afa’afa’atonu

• Upega: oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/
• Telefoni: (832) 416‑2816 (M–Th 10 a.m.–7 p.m., F–Sa 10 a.m.–10 p.m., Su 10 a.m.–4 p.m. Houston time)
• Imeli: [email protected]

Fa’asilasilaga fa’aletulafono ma fa’ato’aga mo tagata o le Manu’a District

Tulaga tausaga: E tatau ona e 21 tausaga po’o sili e fa’atau so’o se oloa RSO. I le fa’atonuga e te fa’amaoni e te tutusa ma lenei tulaga ma e te pu’e mea uma mai le aiga o tamaiti.

Fa’ato’aga:

• E mafai ona fa’aitiitia le malamalama po’o le mālō. E le tatau ona e ta’avale, fa’aaoga va’a, po’o mea maualuga pe’a e faaaoga suauu fa’atulaina po’o vape.
• Fesili ia lau fomai i luma o le faaaoga afai e te pē, fa’apea, e mafatia lou liver, po’o e faaaoga vai-tinu e feso’ota’i ma cannabinoids.
• O le THCa teuina e le psychoactive; o le suauu fa’atulaina e psychoactive. E tatau ona e malamalama le eseese i luma o le faaaoga.
• E le’i fa’amaoniu e le FDA ma e le’i fa’atagaina e fa’ailo, faaola, faitino, po’o puipuia so’o se ma’i. E eseese tulaga ta’asolo.

Fuafuaga fa’aletulafono a tagata: O le toto’otoga e tatau ona e fa’amaonia e mafai ona aofia hemp-derived products <0.3% delta‑9 THC i le Manu’a District. Na OilWell tu’uina atu fa’amaumauga atoa ae e le mafai ona matou fuafua fuafuaga a vamua po’o fa’amau fa’alea’au.

Le a’oa’iga a ABC13 ua ta’u i le talaaga

I le 2019-2023, ABC13 Houston (KTRK) — le ABC affiliate mo le fa’ai’a tele o le U.S. — na fa’aa’oa’o Colin Valencia ma OilWell Cannabis i fitu tala e ese. E lima sui (Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, ma KTRK staff) na saili lo matou poto mo:

• CBD business boom (Sept 2019) — na lagolagosua e Colin, “E le o lo’u manao e fa’i snake oil… ou te manao e maua le mea lelei sili e tu’u atu ai se avanoa.”
• National decriminalization & entrepreneurship (Mar 2021) — na fa’ailoa e “e tele fa’afefea e i ai.”
• Delta‑8 THC investigation (May 2021) — le fesili iconic “Maybe you want to get high”, lagolagoina e Dr. Michael Weaver.
• COVID‑19 vaccine giveaway (Aug 2021) — na fa’amanuia e OilWell ~$35,000 i oloa e fa’ao’o le tui, fa’atulagaina ma le City of Houston.
• Texas Delta‑8 ban (Oct 2021) — na aveese vave e Colin Delta‑8 uma i luma o le fa’amau ma fa’asalalau atu e a’afia isi va’aia narcotics Schedule I.
• Biden marijuana pardon (Oct 2022) — na fa’ailoa e Colin lona talifau marijuana ma lana tōfā e “e le a’afia tagata mo lenei.”
• 4/20 industry “Renaissance” (Apr 2023) — Colin na fa’aa’oa’o hemp i le kamela, fa’ailoa ai le avanoa o le cannabis fa’aletulafono.

O nei tala e fa’atulagaina fa’alea’au, e le mafai ona fa’atau — e maua na’o i le a’oa’iga. O le tulaga lagolagoina o le mataupu lena e mafai ai e tagata o le Manu’a District ona lagona malosi e fa’malosia le OilWell i le fa’amalosia, saogalemu, ma le aiga.

Poto i luga o lo matou fa’atulaga (GENERAL KNOWLEDGE)

Fa’atulagaina e matou te faaaoga

Matou te tofa sources: su’esu’ega faatulagaina o tagata > fa’amaoni atoa > fa’amaumauga a NIH/NCCIH > tusi manatu ta’aloga/mechanistic. Enei e puipuia lo matou fa’apuupuuga mai le fa’alavelave.

Mea e lagolagosua lelei

• CBD: Poto sili i epilepsies (Epidiolex) ma fesoasoani i popole [3] ma mama [4]; e mafai ona fa’ateleina enzymes o le liver i doses maualuga [6].
• Delta‑9 THC: FDA-approved mo lu’itua chemo ma wasting mai AIDS; fesoasoani i mama puupuu, ae afa o popole, tachycardia, ma dependence [13][15].
• Delta‑8 THC: Pharmacologically pei o delta‑9 ae e itiiti poto; poto anti-nausea [9]; fa’amaoniga safety e fa’auo [10][11].
• CBG, CBN, CBC: Mechanistically manaia, ae e itiiti su’esu’ega fa’atagata; matou te aofia mo entourage, e le o monotherapy [7][8][16][17][18][19].
• Terpenes: Limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene e i ai tusa ta’aloga (anti-inflammatory, anxiolytic, CB2 agonism) ae fa’amaoniga fa’atagata e itiiti [20‑28]. O le selectivity o le caryophyllene CB2 e sili [24].

Fa’asalalau masani e matou te aloese

• “CBN o se mea fa’amaoniana mo le moe.” → Sa’o: Fa’amaoniga e fa’evē, e le’i fa’amaonia.
• “Myrcene e fa’amaonia le sedation.” → Sa’o: Ta’aloga lava, e le’i fa’amaonia i tagata.
• “Terpenes e fa’atupu entourage effects.” → Sa’o: Hypothesis, ae e le’i fa’amaonia.
• “THCa e non-psychoactive tōfā.” → Sa’o: E non-psychoactive afai e le vevela; conversion e moni.
• “Delta‑8 e saogalemu ona hemp-derived.” → Sa’o: E psychoactive ma e le’i su’esu’e tele [9‑11].

Fa’atulaga tatala: Fa’amalosia e mafai ona e fa’amaonia

Afai e le mafai ona e totogi $129.99, e mafai ona e maua. O le fa’atulaga moni — lea matou te faaaoga i lo matou lab i Houston.

RSO Sublingual Oil (30 mL)

Cannabinoid	Milligrams
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
TOTAL	16,590 mg

• Live terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Carrier: organic MCT oil
• Concentration: 553 mg/mL

RSO Vape Cartridge (1 g)

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live terpenes: 5%+
• Battery: universal 510-thread

E mafai ona e maua distillates hemp-derived mai suppliers licensed, fa’apipi’i i fa’atulaga i luga, ma toe faia le oloa tasi. O lena agaga a Rick Simpson — aafia fa’asoa — ua fa’afou mo le teri.

Afa’afa’aaaoga lo matou RSO i le Manu’a District: Lisi o fa’atulaga

1. Filifili lau mano – Teuina mo galue aso, fa’atulaina mo le po, vape mo fesoasoani vave.
2. Iloa sao – Faaaoga le dropper graduated (0.1 mL = 55 mg cannabinoids).
3. Amata maualalo, fa’atete – Amata i 0.25–0.5 mL sublingual; faatali 2–3 itula a’e si’itia.
4. Mo le teuina – Tu’u suauu i lalo ole laulau, pu’e 60 sekone, lona. E le tatau ona vevela.
5. Mo le fa’atulaina – Tu’u le tele e te mana’omia i ipu glass e mafai ona vevela. Vevela i le 260°F (125°C) mo 45–60 minute. Ma’alu, ona faaaoga ai sublingual.
6. Mo le vape – Tu’u cartridge i so’o se battery 510-thread. Manava 1–3 puffs pe mana’omia.
7. Teuteu – Pu’e i nofoaga malulu, pogisa. Afa’ase’i le la o le tropics.
8. Togi l lau tali – Togi le dose, taimi, afa’afua. Fa’atete le fa’atulagaina.

Manatu fa’ai’u: Le a’oa’aga o le Manu’a District i matou

Matou te iloa e fa’atulagaina le olaga i le Manu’a District e aiga, tautua, ma le malosi. Ua va’ai outou i uo ma aiga e fa’afefea i le mama maualuga, diabetes, fa’afefea o le moe, ma le fa’ai’uga o le fomai fa’apea. E tatau ona maua outou ni aafia e fa’malosia, saogalemu, ma le poto masani — e le o taunu’uga.

O le talaaga o OilWell na amata mai se maile, se tagata, ma le le talitonu e te’i. O lena agaga na oso e matou e fa’asoa lo matou fa’atulaga, tusia lo matou COA, ma tautala fa’amalosi e uiga o le mea e lagolagosua ma le mea e le’i lagolagosua. Matou te tōfā e lafoa’i atu lo matou RSO o se mea — e mafai ona e pulea, e mafai ona e fa’amaonia, ma e mafai ona e totogi po’o e faia e outou lava.

Fa’atonu nei mo le vaaiga i le Manu’a District – asiasi oilwellcbd.com po’o vala’au (832) 416‑2816. Matou nei e fesili, tu’uina atu COA, ma fesoasoani e maua le dose sa’o mo lau mana’omia.

Tusi Manatu

Rick Simpson & Traditional RSO
RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.
RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.
RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.
RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436‑444. PMID: 22555283.
RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta‑9‑tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197‑203. PMID: 16804518.
RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

GENERAL KNOWLEDGE (Cannabinoid & Terpene Evidence)

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026.
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta‑analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta‑analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza‑Sancho M, López V. Cannabidiol (CBD): A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213‑229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol‑associated hepatotoxicity: A systematic review and meta‑analysis. J Intern Med. 2023;293(6):724‑752. PMID: 36912195.
7. Nachnani R, Raup‑Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204‑212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol (CBG): A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta‑8‑tetrahydrocannabinol (Δ8‑THC): Comparative pharmacology with delta‑9‑THC. Br J Pharmacol. 2022;179(15):3915‑3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta‑8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011‑1028. PMID: 36710464.
11. Abdel‑Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta‑8‑Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno‑Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9‑tetrahydrocannabinolic acid A. Cannabis Cannabinoid Res. 2016;1(1):124‑130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis‑based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143‑1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327‑360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High‑concentration delta‑9‑tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429‑1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366‑371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712‑727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup‑Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206‑213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355‑364. PMID: 36654096.
20. André R, Gomes AP, Pereira‑Leite C, Marques‑da‑Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D‑limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez‑Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez‑Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1‑12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor‑selective pharmacological properties and therapeutic potential of beta‑caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston‑Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene‑based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes‑Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073‑1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha‑humulene: A scoping review. Planta Med. 2024;90(9):664‑674. PMID: 38626911.
28. Menezes IA, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro‑Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid‑terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344‑1364. PMID: 21749363.

ENGLISH

Rick Simpson Oil (RSO) in Manu’a District: A Complete Guide by OilWell Cannabis

If you live in Manu’a District — the remote, breathtaking chain of islands that includes Ofu, Olosega, and Ta’u — you already understand what it means to rely on community, resourcefulness, and the wisdom passed down through generations. Life here moves differently. The ocean provides, the land sustains, and when someone in your aiga (family) faces pain, illness, or the slow wear of chronic disease, you look for solutions that honor both the body and the spirit.

That’s why we’re reaching out to you directly. At OilWell Cannabis, we believe the people of Manu’a District deserve the same access to honest, research-informed cannabinoid medicine that has helped thousands of Texans reclaim their lives from chronic pain, sleep disorders, anxiety, and the side effects of conventional treatments. We’re not here to sell you “snake oil.” We’re here to give you the best possible version of the truth — backed by science, guided by experience, and delivered with the same respect you show your neighbors.

The story behind RSO: Rick Simpson’s legacy and its limits

Who was Rick Simpson?

Rick Simpson was a power engineer from Nova Scotia, Canada, who stumbled into cannabis advocacy after a workplace injury in 1997 left him with chronic pain, tinnitus, and a medical system that had no answers. When conventional medicine failed, cannabis gave him relief . In 2003, after reportedly treating three skin lesions with homemade cannabis oil, Simpson claimed they disappeared within four days — an event that became the origin story of “Rick Simpson Oil” .

Important context: Those events are personal testimony, not peer‑reviewed medical proof. Simpson never conducted a clinical trial, never published a study, and never had his outcomes independently verified . Yet his story spread like wildfire after the 2005 documentary Run From the Cure, turning RSO into a global symbol of hope for cancer patients, chronic pain sufferers, and anyone let down by institutional medicine .

Simpson’s 60‑gram, 90‑day protocol

Simpson believed that a cancer patient needed to consume roughly 60 grams of high‑THC oil over about 90 days. His dosing schedule started at a half‑grain of rice three times daily and escalated to about 1 gram per day by week five . At that peak, a patient would be ingesting 600–900 mg of delta‑9 THC every day — doses far beyond anything studied in controlled settings .

Why Simpson’s approach was incomplete

Simpson’s oil was made from a single indica strain, extracted with naphtha or isopropyl alcohol (both non‑food‑grade solvents), and processed over high heat that destroyed every volatile terpene. The result was a nearly black, tar‑like product with no standardized potency, no lab testing, and no safety verification .

That worked in an era when cannabis was completely illegal, but it left patients exposed to:

• Residual solvents that may contain benzene or other carcinogens
• Unpredictable THC levels from batch to batch
• Zero terpene content, eliminating any potential entourage benefit
• No ability to control psychoactivity for daytime use

Simpson’s claims of “curing” cancer were never supported by human trials. The National Cancer Institute (NCI) acknowledges preclinical interest but does not endorse cannabis as a cancer treatment . The FDA has approved only isolated cannabinoids (Epidiolex, dronabinol) for specific indications — never the whole cannabis plant [1].

What Simpson got right

He made cannabinoids impossible to ignore. He gave his oil away for free, taught others to make it, and created a movement that forced scientists and regulators to take cannabis seriously . That legacy matters — and it’s the reason we built something better.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell RSO (Manu’a District edition)
Source material	Single high‑THC indica strain	Multi‑cannabinoid blend from multiple hemp sources
Extraction	Naphtha or isopropyl alcohol	Solvent‑free blending of pure distillates in organic MCT oil
Cannabinoid profile	60–90% delta‑9 THC, uncontrolled	7 cannabinoids at precise milligram ratios (see formula below)
Terpene content	Destroyed by heat	Live terpenes at 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
Standardization	None; every batch different	Lab‑tested; each bottle contains 553 mg/mL total cannabinoids
Lab testing	Never performed	Full panel: potency, terpenes, pesticides, heavy metals, residual solvents, microbes
Residual solvents	Naphtha may contain benzene	Zero solvents; MCT oil carrier only
Dosing precision	Syringe‑based guesswork	Graduated dropper delivers 0.1 mL increments (55.3 mg cannabinoids)
Product formats	One thick oil only	Sublingual oil + vape cartridge (format‑specific formulas)
THCa preservation	Fully decarboxylated	1,500 mg THCa kept raw; you decide when (or if) to activate
Evidence approach	Anecdotes only	Anchored to peer‑reviewed literature; every compound has a citation

About OilWell Cannabis: From a paralyzed dog to a mission that spans oceans

The origin: Bentley’s story

OilWell was born in Houston, Texas, but its heartbeat belongs to a dog named Bentley. When Bentley fell ill, veterinarians recommended euthanasia — his pain meds would destroy his organs, they said, and paralysis in his hind legs made life unbearable. Colin Valencia, our founder, refused to accept that verdict. He had already lost too many friends to violence in the McAllen‑Reynosa borderlands; he couldn’t lose his dog, too.

A rescue worker named Jessica asked Colin the question that changed everything: “You’ve moved how many tons of weed and you’ve never heard of CBD?” That blind spot became a mission. Colin learned to create a CBD golden paste for Bentley — a blend of organic turmeric, coconut oil, black pepper, and CBD oil. Within days, Bentley got up, walked over to Colin, and brought him his ball. From paralyzed to playing fetch. Dogs don’t respond to placebo. That was real cannabinoid medicine.

Bentley lived another ten years, dying naturally at age twenty. During that decade, Colin developed precision formulas for every age‑related condition Bentley faced: neurodegeneration → CBG (neuroprotective, PPARγ agonism); dementia → CBC (neurogenesis); glaucoma → THCa (CB1 agonism, intraocular pressure); arthritis → multi‑pathway anti‑inflammation (CBD, CBG, THCa, caryophyllene). Single cannabinoids were never enough. Bentley taught us that synergy matters.

Colin’s own battle: PTSD and benzo withdrawal

Colin’s path didn’t stop with Bentley. He personally struggled with severe PTSD and a benzodiazepine addiction. When he decided to quit Xanax cold turkey — a dangerous feat — he used the same multi‑cannabinoid knowledge that kept Bentley alive. The Peace Gummies formula was born during midnight experiments in the throes of benzo withdrawal. Today, Colin still uses the vape form to manage his insomnia and PTSD. He lives what our products are designed to do.

From the border to the Baylor Medical Center

Colin grew up in McAllen, Texas, one of the most economically challenged and dangerous border regions in the U.S. He learned cannabis the traditional way — in the shadows, before legalization. But he also became a formally trained software engineer and did custom development for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination — deep plant knowledge plus medical‑grade precision — is what makes OilWell different.

The OilWell RSO philosophy (the four pillars)

1. Accessibility over gatekeeping – No medical card needed. Anyone 21+ can order. We ship nationwide and internationally, including to U.S. territories like Manu’a District. Simpson gave his oil away; we sell a lab‑tested product and publish the recipe so you can make your own if you choose.

2. Patient‑controlled potency – Our sublingual oil contains 1,500 mg of raw THCa. You decide: use it raw (non‑psychoactive) or decarboxylate it at home into ~1,315 mg of delta‑9 THC. Combined with the existing 90 mg delta‑9 THC, that’s ~1,405 mg of total THC—full‑potency RSO, legal because the conversion happens after you purchase.

3. Open‑source formulas – Every milligram is published. If you can’t afford $129.99, you can source the same hemp‑derived distillates and recreate the formula yourself. That’s the same spirit that saved Bentley.

4. Evidence‑informed, not evidence‑overstating – We anchor every claim to peer‑reviewed literature (see the GENERAL KNOWLEDGE section). We don’t promise cures. We promise transparency.

The legal framework: Farm Bill compliance and THCa conversion

Our RSO Sublingual Oil contains only 90 mg of delta‑9 THC in the entire 30 mL bottle — well under the 0.3% federal limit set by the 2018 Farm Bill. All cannabinoids are hemp‑derived. The product is Farm Bill compliant at the point of sale, which makes it legal to purchase, possess, and ship to most U.S. jurisdictions.

THCa conversion chemistry:

• 1,500 mg THCa × 0.877 (decarboxylation factor) = ~1,315 mg delta‑9 THC after heating at 260°F (125°C) for 45–60 minutes.
• Combined with the 90 mg delta‑9 THC already present, you control whether the bottle stays non‑psychoactive (raw) or becomes full‑potency RSO.

Important legal notice for Manu’a District residents:
THCa converts to delta‑9 THC when heated. While our product meets federal hemp standards, local laws in American Samoa may differ. It is your responsibility to verify that hemp‑derived products with <0.3% delta‑9 THC are permitted in your jurisdiction before ordering. OilWell provides full documentation, Certificates of Analysis (COAs), and receipts for every shipment. We assume no liability for customs decisions or local enforcement actions.

Solvent‑free production & third‑party testing

Traditional RSO used naphtha or isopropyl alcohol — solvents that can leave behind benzene and other carcinogens. Our process is solvent‑free: we blend high‑purity cannabinoid distillates and isolates in organic MCT oil, a food‑grade carrier that improves sublingual absorption and eliminates the tar‑like taste of old‑school RSO.

Every batch is tested by independent labs for:

• Potency (HPLC/UHPLC, ±2% accuracy)
• Heavy metals (arsenic, cadmium, lead, mercury — all below FDA limits)
• Pesticides (400+ compounds via LC‑MS/MS and GC‑MS/MS)
• Residual solvents (headspace GC, FDA Class 3 limits <5,000 ppm)
• Microbial contaminants (E. coli, Salmonella, Aspergillus, etc.)

COAs are available on request and on our website. You can verify what’s in every bottle before it reaches your doorstep in Manu’a District.

Our products: RSO Sublingual Oil & RSO Vape Cartridge

RSO Sublingual Oil – $129.99

• Volume: 30 mL (1 fl oz)
• Total cannabinoids: 16,590 mg (553 mg/mL)
• Cannabinoid breakdown per bottle:
  • CBD: 4,500 mg – anxiolytic, anti‑inflammatory, neuroprotective [3][4]
  • CBG: 3,000 mg – neuroprotection, PPARγ agonism, potential benefit for IBD [7][8]
  • Delta‑8 THC: 6,000 mg – anti‑nausea, appetite stimulation, less intense psychoactivity than delta‑9 [9]
  • THCa: 1,500 mg – raw, non‑psychoactive; converts to ~1,315 mg THC if decarbed [12]
  • Delta‑9 THC: 90 mg – baseline THC, well below 0.3% limit
  • CBN: 750 mg – marketed for sleep (though human evidence is still emerging) [16][17]
  • CBC: 750 mg – anti‑inflammatory, neurogenic properties (preclinical) [18][19]
• Live terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Carrier: organic MCT oil
• Dropper: graduated in 0.1 mL increments (55.3 mg cannabinoids per click)
• Onset: 15–45 minutes (sublingual)
• Peak: 1–2 hours
• Duration: 4–6 hours
• Bioavailability: 13–19%
• Doses per bottle: ~40–60 depending on serving size

RSO Vape Cartridge – $49.99

• Volume: 1 gram
• Total cannabinoids: 900+ mg
• Cannabinoid percentages: CBD 30%, CBG 20%, delta‑8 THC 15%, THCa 10%, CBN 10%, CBC 10%
• Live terpenes: 5%+
• Thread: 510‑thread universal battery (available locally or online)
• Onset: 1–2 minutes (fastest route)
• Peak: 10–15 minutes
• Duration: 2–4 hours
• Bioavailability: 10–35%
• Auto‑decarb: vaping at 400–450°F instantly converts THCa → delta‑9 THC

When to use each format in Manu’a District

Situation	Best Format	Why
Acute pain flare (e.g., after a long day fishing or working the plantation)	Vape	1–2 minute onset, immediate relief
Chronic pain management (arthritis, back pain)	Sublingual	4–6 hour duration, sustained anti‑inflammatory coverage
Sleep support (trouble falling or staying asleep)	Sublingual (1–2 mL before bed)	Provides 25–50 mg CBN + full cannabinoid entourage
Daytime functional relief (no high, need to work, drive)	Sublingual raw (no heat)	THCa stays non‑psychoactive; you remain clear‑headed
Nighttime full‑potency (when you want the therapeutic “high”)	Sublingual decarbed or Vape	Activates the full 1,405 mg THC equivalent
Nausea from chemo or stomach illness	Vape + Sublingual	Vape for breakthrough nausea; sublingual for baseline appetite
Anxiety or stress (community gatherings, family pressures)	Sublingual (0.3 mL raw)	CBD + CBG calm without impairment [3]

Condition‑specific usage contexts (Manu’a District focused)

Important disclaimer: These are educational examples, not medical prescriptions. Always consult your healthcare provider before starting any cannabinoid regimen, especially if you are pregnant, nursing, have liver disease, or take medications that interact with cannabinoids. Do not operate boats, vehicles, or machinery if using psychoactive doses.

Chronic pain (e.g., arthritis, old injuries from field work)

• Daytime: 0.3–0.5 mL sublingual raw (CBD + CBG + THCa) every 6–8 hours. Keeps inflammation down without a high.
• Nighttime: 0.5–1.0 mL sublingual decarbed before bed. Combines THC’s pain relief with CBN’s sleep support.
• Evidence: CBD’s anti‑inflammatory and analgesic properties [4]; delta‑9 THC’s short‑term pain benefit [13]; beta‑caryophyllene’s CB2 activation [24]; THCa’s COX‑2 inhibition [12].

Sleep disorders (common in older adults)

• Before bed: 1.0–2.0 mL sublingual (delivers 25–50 mg CBN).
• If you wake during the night: 1–2 vape puffs for rapid onset.
• Evidence: CBN at 20–50 mg doses has been explored for sleep [16][17]; cannabis‑based sleep literature acknowledges the need for better trials but shows moderate subjective improvement [17].

Anxiety & stress (family, economic, or isolation pressures)

• Daytime functional: 0.3 mL sublingual raw (CBD 15 mg + CBG 10 mg).
• If anxiety peaks: 1–2 vape puffs for quick calming.
• Evidence: CBD anxiolysis is supported in small clinical samples [3]; CBG’s 5‑HT1A activity is plausible but still preclinical [7][8]; limonene may buffer THC‑induced anxiety [20].

Chemotherapy‑related nausea & appetite (for those traveling to LBJ or off‑island treatment)

• Pre‑chemo: 0.5–1.0 mL sublingual 1 hour before infusion.
• Breakthrough nausea: 2–3 vape puffs as needed.
• Post‑treatment: 0.5 mL sublingual every 6 hours.
• Evidence: delta‑8 THC shows antiemetic promise [9]; delta‑9 THC is FDA‑approved for chemo nausea in synthetic form [1][13]; CBD may reduce anxiety around treatment [3].

Delivery to Manu’a District: How you can get OilWell RSO

We are based in Houston, Texas, but we ship nationwide and internationally. Here’s what you need to know about receiving RSO in the Manu’a islands.

Domestic U.S. shipping (including American Samoa)

• Carrier: USPS Priority Mail, FedEx Ground, or UPS Ground
• Typical transit: 5–7 business days from Houston to Pago Pago, plus local distribution to Ofu, Olosega, or Ta’u.
• Packaging: Discreet, no cannabis branding visible. Temperature‑stable for tropical climates.
• Tracking: Provided for every order.
• Signature: Optional signature‑required service available (recommended if you’re concerned about porch delivery).
• Customs documentation: Full COA, hemp‑derived product declaration, and receipt included.

Shipping fees

• Flat rate: $12.99 for orders under $150; FREE for orders $150+.
• International (if you live outside the U.S.): We ship to many countries. Minimum flat‑fee shipping applies; excessive costs are billed separately. You accept all customs and legal responsibility.

Note: While our product meets federal hemp standards, American Samoa may have additional restrictions on cannabinoid imports. Please verify local regulations before ordering. We provide all documentation to facilitate customs clearance, but we cannot guarantee entry.

How to order

• Online: oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/
• Phone: (832) 416‑2816 (M–Th 10 a m–7 p m, F–Sa 10 a m–10 p m, Su 10 a m–4 p m Houston time)
• Email: [email protected]

Legal notice & safety warnings for Manu’a District customers

Age requirement: You must be 21 years or older to purchase any RSO product. By placing an order, you confirm you meet this age and that you will keep all products out of reach of children.

Product warnings:

• May cause drowsiness or impairment. Do not drive, operate boats, or use heavy machinery after consuming activated (decarbed) oil or vape.
• Consult your healthcare provider before use if you are pregnant, nursing, have liver disease, or take medications that interact with cannabinoids.
• Raw THCa is non‑psychoactive; decarboxylated oil is psychoactive. Understand the difference before use.
• This product is not evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.

Local law responsibility: It is your responsibility to confirm that hemp‑derived products with <0.3% delta‑9 THC are legal to import and possess in Manu’a District. OilWell provides full documentation but assumes no liability for customs seizures or local enforcement.

Why OilWell? The ABC13 media record speaks for itself

Between 2019 and 2023, ABC13 Houston (KTRK) — the ABC affiliate serving America’s fourth‑largest city — featured Colin Valencia and OilWell Cannabis in seven separate news segments. Five different reporters (Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff) sought our perspective on:

• The CBD business boom (Sept 2019) – where Colin first said, “I’m not trying to sell people snake oil… I want them to have the best possible version to give it a fair shot.”
• National decriminalization & entrepreneurship (Mar 2021) – highlighting that “pain comes in a lot of different forms.”
• Delta‑8 THC investigation (May 2021) – the iconic “Maybe you want to get high” exchange, balanced by Dr. Michael Weaver’s medical caution.
• COVID‑19 vaccine giveaway (Aug 2021) – OilWell donated ~$35,000 in product to encourage vaccination, coordinating with the City of Houston.
• Texas Delta‑8 ban (Oct 2021) – Colin proactively removed all Delta‑8 before enforcement and warned other operators they were shipping Schedule I narcotics.
• Biden marijuana pardon (Oct 2022) – revealing Colin’s own marijuana conviction history and his hope that “people not get hurt for this anymore.”
• 4/20 industry “Renaissance” (Apr 2023) – Colin growing hemp on camera, framing the current moment as an opportunity to enjoy legal cannabis innovation.

These features are independently produced, editorially controlled news segments. They cannot be purchased — only earned. That level of sustained media trust is why Manu’a District residents can feel confident that OilWell stands for transparency, safety, and community.

The science behind our formula (GENERAL KNOWLEDGE summary)

Evidence hierarchy we use

We rank sources as: human clinical trials > systematic reviews > NIH/NCCIH institutional summaries > preclinical/mechanistic literature. This keeps our claims honest and prevents hype.

What the strongest evidence supports

• CBD: Best evidence for rare epilepsies (Epidiolex) and modest support for anxiety [3] and pain [4]; liver enzyme elevation possible at high doses [6].
• Delta‑9 THC: FDA‑approved for chemo nausea and AIDS‑related wasting; short‑term pain relief possible, but dosage‑dependent risks of anxiety, tachycardia, and dependence [13][15].
• Delta‑8 THC: Pharmacologically similar to delta‑9 but less potent; anti‑nausea potential [9]; safety profile still emerging [10][11].
• CBG, CBN, CBC: Mechanistically interesting, but human trials are sparse; we include them for entourage potential, not as proven monotherapies [7][8][16][17][18][19].
• Terpenes: Limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene each have preclinical signals (anti‑inflammatory, anxiolytic, CB2 agonism) but robust human proof is limited [20‑28]. Caryophyllene’s CB2 selectivity is the most compelling [24].

Common overstatements we avoid

• “CBN is a proven sleep aid.” → More accurate: Evidence is weak and dated; no validated trials yet [16][17].
• “Myrcene guarantees sedation.” → More accurate: Preclinical only; human proof is lacking [23].
• “Terpenes always create entourage effects.” → More accurate: Hypotheses are plausible but clinical confirmation is sparse [20][29].
• “THCa is always non‑psychoactive.” → More accurate: It’s non‑psychoactive unless heated; conversion to THC is real [12].
• “Delta‑8 is safe because it’s hemp‑derived.” → More accurate: It’s psychoactive and less studied than delta‑9 [9‑11].

The open‑source formulas: transparency you can verify

If you can’t afford our $129.99 bottle, you can still benefit. Below is the exact formula — the same one we use in our Houston lab.

RSO Sublingual Oil (30 mL)

Cannabinoid	Milligrams
CBD	4,500 mg
CBG	3,000 mg
Delta‑8 THC	6,000 mg
THCa	1,500 mg
Delta‑9 THC	90 mg
CBN	750 mg
CBC	750 mg
TOTAL	16,590 mg

• Live terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Carrier: organic MCT oil
• Concentration: 553 mg/mL

RSO Vape Cartridge (1 g)

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta‑8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live terpenes: 5%+
• Battery: universal 510‑thread

You can source hemp‑derived distillates from licensed suppliers, blend them in the ratios above, and recreate the same product we sell. That’s the Rick Simpson spirit — free access to medicine — updated for the modern era.

How to use our RSO in Manu’a District: a step‑by‑step guide

1. Decide your goal – Raw for daytime function, decarbed for nighttime potency, vape for fast relief.
2. Measure precisely – Use the graduated dropper (0.1 mL = 55 mg cannabinoids).
3. Start low, go slow – Begin with 0.25–0.5 mL sublingual; wait 2–3 hours before increasing.
4. For raw use – Place oil under tongue, hold 60 seconds, swallow. No heating.
5. For decarbed use – Transfer desired amount to an oven‑safe glass dish. Heat at 260°F (125°C) for 45–60 minutes. Cool, then administer sublingually.
6. For vape use – Attach cartridge to any 510‑thread battery. Inhale 1–3 puffs as needed.
7. Store properly – Keep in a cool, dark place. Avoid prolonged exposure to tropical sun.
8. Track your response – Note dosage, time, effects. Adjust gradually.

Final thoughts: Why Manu’a District matters to us

We know that life in Manu’a District is defined by aiga, tautua (service), and resilience. You’ve seen friends and family struggle with chronic pain, diabetes, sleep trouble, and the limits of what the local clinic can provide. You deserve options that are transparent, safe, and rooted in real science — not miracles.

OilWell’s story began with a dog, a man, and a refusal to give up. That same spirit drives us to share our formulas, publish our lab results, and speak honestly about what the evidence does and doesn’t say. We hope our RSO offers you a tool — one you can control, one you can trust, and one you can afford either by purchase or by making it yourself.

Order today for Manu’a District delivery – visit oilwellcbd.com or call (832) 416‑2816. We’re here to answer your questions, provide COAs, and help you find the right dose for your needs.

References

Rick Simpson & Traditional RSO
RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.
RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.
RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.
RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436‑444. PMID: 22555283.
RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta‑9‑tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197‑203. PMID: 16804518.
RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

GENERAL KNOWLEDGE (Cannabinoid & Terpene Evidence)

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026.
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta‑analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta‑analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza‑Sancho M, López V. Cannabidiol (CBD): A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213‑229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol‑associated hepatotoxicity: A systematic review and meta‑analysis. J Intern Med. 2023;293(6):724‑752. PMID: 36912195.
7. Nachnani R, Raup‑Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204‑212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol (CBG): A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta‑8‑tetrahydrocannabinol (Δ8‑THC): Comparative pharmacology with delta‑9‑THC. Br J Pharmacol. 2022;179(15):3915‑3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta‑8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011‑1028. PMID: 36710464.
11. Abdel‑Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta‑8‑Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno‑Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9‑tetrahydrocannabinolic acid A. Cannabis Cannabinoid Res. 2016;1(1):124‑130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis‑based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143‑1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327‑360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High‑concentration delta‑9‑tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429‑1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366‑371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712‑727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup‑Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206‑213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355‑364. PMID: 36654096.
20. André R, Gomes AP, Pereira‑Leite C, Marques‑da‑Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D‑limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez‑Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez‑Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1‑12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor‑selective pharmacological properties and therapeutic potential of beta‑caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston‑Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene‑based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes‑Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073‑1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha‑humulene: A scoping review. Planta Med. 2024;90(9):664‑674. PMID: 38626911.
28. Menezes IA, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro‑Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid‑terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344‑1364. PMID: 21749363.

---